ArticleNature medicine2024
Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease.
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Plasma Proteomic Analysis ofmedRxiv : the preprint server for health sciences · 2026Article
- Levetiracetam prevents Aβ production through SV2a-dependent modulation of APP processing in Alzheimer's disease models.Science translational medicine · 2026Article
- The effect of human-specific genetic variants on neuronal spinogenesis.Frontiers in genetics · 2026Review
- AD diagnosis model based on fusion of heterogeneous brain imaging and genomic data.Frontiers in neuroscience · 2026Article
- Generational effects in Down syndrome: Enriched environment enhances functionality without reducing Alzheimer's disease risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- CTAD taskforce: genetic therapies in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Review
- The obesity paradox in cognitive decline: Impact of BMI dynamics and APOE genotypes across various cognitive status.Diabetes, obesity & metabolism · 2025Article
- Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease.Nature communications · 2025Article
- Sequential Proteomic Analysis Reveals the Key APOE4-Induced Pathological and Molecular Features at the Presymptomatic Stage in Alzheimer's Disease Mice.CNS neuroscience & therapeutics · 2025Article
- Ethical disclosure of biomarkers for Alzheimer risk in Latin American participants.Frontiers in dementia · 2025Article
- The role of inflammation in neurological disorders: a brief overview of multiple sclerosis, Alzheimer's, and Parkinson's disease'.Frontiers in neurology · 2024Review
- Brain health in older adults: At the crossroads of frailty and resilience.Journal of Alzheimer's disease reportsReview
- Sex variation in the relationship betweenAlzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Erratum for
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
38886628What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.